Effective 4/15/2026, Cigna updated Medical Coverage Policy 0558 (MDC 08: Orthopedics & Musculoskeletal) to enumerate new CPT Category III and other recent procedure codes and short descriptions in the effective-date note. Examples include codes for biodegradable hydrogel instillation, autologous muscle cell therapy harvesting/administration, first carpometacarpal joint prosthetic arthroplasty (1003T), and device/technique-specific services (0990T–1025T). The policy references CPT® 2025 for coding and situates these additions within Cigna’s broader musculoskeletal coverage resources (e.g., Miscellaneous Musculoskeletal Procedures, Subtalar Joint Implantation), but the excerpt does not include coverage determinations or medical necessity language. Use the effective-date note and related musculoskeletal policies for coverage criteria and benefit guidance.
April 15, 2026 Revision: Newly Enumerated Procedure Codes and Descriptions
This revision is effective 4/15/2026 and updates the Medical Coverage Policy identified as 0558 under Cigna’s MDC 08: Orthopedics & Musculoskeletal (Bones/Joints) grouping. The document lists a series of CPT Category III and other newer or descriptive codes added or described in the effective-date note portion of the policy text (examples include 0990T, 0991T, 0994T, 0995T, 0999T, 1000T, 1001T, 1003T, and 1025T). Those entries are presented with short procedure descriptions reflecting new device- or technique-specific services (for example, biodegradable hydrogel instillation, autologous muscle cell therapy, and a first carpometacarpal joint arthroplasty prosthetic replacement).
The revision also emphasizes that the policy's coding references reflect Current Procedural Terminology (CPT ® ) © 2025 American Medical Association and ties these code entries into the broader related coverage resources list for musculoskeletal procedures and subtalar joint implantation. The effective-date note functions as the primary indicator of newly enumerated or clarified procedure descriptors within this policy iteration.
Placement Within Cigna’s Musculoskeletal Coverage Framework and Related Resources
The policy text explicitly references a wide set of related coverage resources under the Musculoskeletal umbrella. Items listed include Miscellaneous Musculoskeletal Procedures and Subtalar Joint Implantation (Subtalar Arthroereisis), indicating this policy sits within a suite of orthopedic and musculoskeletal coverage documents. Other listed resources connect to disparate service areas (for example, Peripheral Nerve Destruction for Pain Conditions, Electrical Stimulation Therapy and Devices in a Home Setting, and Scar Revision), which suggests cross-references or related guidance for certain musculoskeletal interventions.
This grouping signals that the policy's scope encompasses miscellaneous procedures and device- or technique-specific coverage considerations rather than a single focused procedure. The inclusion of both procedural and device-oriented items (e.g., implantable monitoring, arthroplasty prosthetic replacement) in the related resources aligns the policy with multidisciplinary treatment modalities within musculoskeletal care.
Enumerated Procedure Descriptions and Representative CPT Entries in the Effective-Date Note
The effective-date note contains specific procedure descriptors tied to CPT Category III codes and unique service descriptors. Examples include: 0990T (transcervical instillation of biodegradable hydrogel materials, intrauterine), 0991T (cystourethroscopy with low-energy lithotripsy and acoustically actuated microspheres), 0994T/0995T (endovascular delivery of aortic wall stabilization drug therapy with percutaneous or open approaches), and 0999T–1001T (autologous muscle cell therapy harvesting and administration into urethral and anal sphincters). Also listed is 1003T (arthroplasty, first carpometacarpal joint with prosthetic replacement) and 1025T (alternating electric fields dosimetry and delivery-simulation modeling).
While some described services (for example, aortic wall stabilization delivery codes) are outside classic orthopedics, their presence in this effective-date listing indicates the policy documents updates across multiple clinical domains and highlights the inclusion of emerging or device-specific procedures within Cigna’s coding and coverage catalog as of the effective date.
Coding Reference and Absence of Explicit Coverage Determinations in the Excerpt
The policy clearly states that Current Procedural Terminology (CPT ® ) © 2025 American Medical Association: Chicago, IL. is the coding reference used for the listed procedures. This affirms that the codes and descriptions reflected in the effective-date note are aligned with the 2025 CPT edition as cited in the policy text. The document therefore relies on the AMA’s CPT nomenclature for the procedural items it enumerates.
No explicit coverage determinations, criteria, or benefit-language (such as medically necessary vs investigational) are present in the provided excerpt. Instead, the excerpt functions primarily as a coding and cross-reference update within the broader MDC 08 musculoskeletal heading and points readers to related coverage resources for more detailed policy content.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.